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Background:  Mammalian hibernation biology is now known to be mediated by
delta opioids. The altered myocellular physiology of hibernation closely parallels
that of hypothermic ischemia used to protect the heart for cardiac surgery.
Methods and Results:  The present study examined the interaction of delta opioid
agonists and antagonists on myocardial tolerance to ischemia. By means of a non-
hibernating isolated rabbit heart model, functional and metabolic myocardial
parameters were assessed during nonischemic baseline and postischemic recovery
periods. Control hearts with standard cardioplegic protection alone were compared
with those with cardioplegia plus preperfusion with a delta opioid agonist, a delta
opioid antagonist, or both. All hearts were then subjected to 2 hours of global
ischemia. Compared with cardioplegia alone, postischemic left ventricular devel-
oped pressure, coronary flows, and myocardial oxygen consumption were all
increased with administration of delta opioid agonists and decreased below baseline
with delta opioid antagonists. Functional recovery of left ventricular developed
pressure was improved with opioids (control hearts: 36 ± 3 mm Hg vs hearts with
cardioplegia plus delta opioid agonist: 65 ± 5 mm Hg, P < .01) and inhibited with
antagonists (control hearts: 36 ± 3 mm Hg vs hearts with cardioplegia plus delta
opioid antagonist: 17 ± 5 mm Hg, P < .05), and true to form, the protective opioid
effect was negated when combined with an antagonist (control hearts: 36 ± 3 mm
Hg vs hearts with cardioplegia plus delta opioid agonist and delta opioid antagonist:
42 ± 4 mm Hg, P = not significant).
Conclusions:  This study demonstrates that cardiac tolerance to ischemia may be
mediated by delta opioids.
Presently, cardioplegia and hypothermia provide considerable myocar-dial protection during the induced ischemia of cardiac surgery.However, poor myocardial tolerance to ischemia, as seen with periop-erative ventricular dysfunction and stunning, remain significant clinicalproblems. Interestingly, the subcellular and molecular myocyticchanges seen during mammalian hibernation closely parallel the altered
myocyte physiology seen with hypothermic cardioplegic arrest. Both undergo deple-
tion of energy stores, intracellular acidosis, hypoxia, hypothermia, and cellular vol-
ume shifts. Yet the myocardium of the hibernating mammal can endure these alter-
ations resiliently for months, whereas the duration of induced ischemia tolerated
surgically is limited to hours. Through its effective reversal by opiate antagonists, an
opiate nature to this hibernation-mediated ischemic tolerance has been established.
Physical chemistry analysis indicates that these peptides are similar to delta opioids,
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between perfusate and coronary effluent flow, and c is the Bunsen
solubility coefficient of O2 in perfusate at 37°C (22.7 µL O2 ·
atm–1 · mL–1 perfusate). The PO2 of the perfusate was 665 mm Hg.
Coronary flow was measured by performing timed collections of
the pulmonary effluent flow with a graduated cylinder. Oxygen
extraction was calculated as follows:
O2 Extraction = MVO2/Oxygen content in the perfusate. 
Wet and dry myocardial weights and calculation of water con-
tent comparatively assessed myocardial edema in each specimen.
Wet weight of the heart was determined at the conclusion of each
experiment after trimming the great vessels and fat and blot drying
with 9-layer cotton gauze. The left ventricular wall was weighed,
desiccated for 48 hours at 65°C, and reweighed. Water content was
determined by the following formula:
(1 – Dry weight/Wet weight)/100%. 
A section of the LV was prepared for histopathologic examination.
Each of these methods has been previously reported.1,2
After Langendorff instrumentation was completed and calibrations
had been performed, left ventricular balloon volumes were varied over
a range of values to construct modified isovolumic left ventricular
function curves. The identical volumes were maintained during base-
line and reperfusion conditions. Baseline data were obtained after an
equilibration period of 30 minutes. During the baseline period, data
were obtained with hearts maintained at 37°C with a water-jacketed
organ bath. A Khuri Regional Tissue pH Monitor-intramural pH elec-
trode (Vascular Technology, Chelmsford, Mass) was placed in the left
ventricular free wall during infusions to observe pH changes. To
observe metabolic changes in tissue nucleotides (adenosine triphos-
phate, adenosine monophosphate, adenosine diphosphate, and insosine
5´-monophosphate) and nucleosides (adenosine, inosine, hypoxan-
thine, and xanthine), heart biopsy specimens were rapidly frozen in liq-
uid nitrogen at baseline or at 15 minutes of reperfusion and then
lyophilized. Tissue was processed as previously described by our lab-
oratory.3 High-performance liquid chromatography was performed
with a Waters µBondapak C18 column (Milford, Mass). The spec-
trophotometric detector was set at 254 nm for determination of
nucleotides and nucleosides and at 210 nm for measurement of phos-
which can mimic induction of natural hibernation when
administered to mammalian species. The present study exam-
ined the interaction of delta opioid agonists and antagonists
and their effect on myocardial functional recovery after glob-
al ischemia in a nonhibernating mammalian model.
Methods
Rabbits (2.2-2.7 kg) were anesthetized with sodium pentobarbi-
tal (45 mg/kg administered intravenously) and heparinized (700
U/kg administered intravenously). The heart was rapidly excised and
immersed in ice-cold physiologic salt solution (PSS), pH 7.4, con-
taining 118.0 mmol/L NaCl, 4.0 mmol/L KCl, 22.3 mmol/L
NaHCO3, 11.1 mmol/L glucose, 0.66 mmol/L KH2PO4, 1.23
mmol/L MgCl2, and 2.38 mmol/L CaCl2. The aorta was cannulated
in the Langendorff mode, and the heart was perfused with PSS equil-
ibrated with 95% O2-5% CO2 at 37°C and passed twice through fil-
ters with a 3.0-µm pore size. Perfusion pressure was maintained at
80 mm Hg. An incision was made in the left atrium, and a fluid-filled
latex balloon was passed through the mitral orifice and placed in the
left ventricle. In this established model, the balloon was connected
to a pressure transducer for continuous measurement of left ventric-
ular pressure and the first derivative of left ventricular pressure
(dP/dt). The venae cavae and the azygos vein were ligated. The pul-
monary artery was cannulated to enable timed collection measure-
ments of coronary flow and was connected to an oxygen meter
(Diamond, Inc, Ann Arbor, Mich) for continuous measurement of
the oxygen partial pressure. The analog signals were continuously
recorded on a pressurized ink chart and digitized to an online com-
puter. Cardiac function was characterized by dP/dt and left ventric-
ular developed pressure (LVDP), where LVDP is the isovolumetric
pressure generated by the left ventricle defined as peak systolic pres-
sure minus end-diastolic pressure. Myocardial oxygen consumption
(MVO2) was calculated as follows:
MVO2 = CF × [(PaO2 – PvO2) × (c/760)],
where CF is coronary flow (in milliliters per minute per gram),
PaO2 – PvO2 is the difference in the PO2 (in millimeters of mercury)
TABLE 1. Postischemic functional and metabolic indices
n LVDP (mm Hg) CF (mL/min) MVO2 (µL O2/min) +dP/dt (mm Hg/s) –dP/dt (mm Hg/s)
CON 10 36 ± 3 60 ± 4 45 ± 3 37 ± 3 33 ± 2
DPDPE 4 34 ± 4 76 ± 5 71 ± 7* 43 ± 7 38 ± 6
DADLE 7 65 ± 5* 80 ± 5 73 ± 5* 69 ± 7* 66 ± 6*
Nx 2 × 10–4 4 17 ± 5* 47 ± 19 37 ± 15 27 ± 18 27 ± 16
Nx 2 × 10–5 4 27 ± 8 80 ± 15 58 ± 10 27 ± 9 26 ± 8
Nx 2 × 10–6 4 17 ± 6* 57 ± 8 46 ± 5 19 ± 6 16 ± 5
Nx 2  × 10–5 + DADLE 4 42 ± 4 72 ± 14 63 ± 10 45 ± 6 38 ± 4
Nx 2 × 10–6 + DADLE 4 26 ± 4 64 ± 5 58 ± 4 30 ± 5 27 ± 4
Nx 2 × 10–7 + DADLE 5 45 ± 4 60 ± 7 65 ± 6* 49 ± 5 43 ± 5
Nx 2 × 10–9 + DADLE 4 44 ± 3 87 ± 12* 79 ± 9* 50 ± 2 42 ± 2
BNTX 4 53 ± 9* 88 ± 5* 78 ± 5* 55 ± 10 47 ± 9
NTB 4 23 ± 5 76 ± 18 58 ± 11 24 ± 6 23 ± 7
Data are expressed as means ± SD. Preischemia solution administration: CON, standard cardioplegia; Nx, naltrexone delta 1 and 2 antagonist expressed
in molar concentrations. Postischemia functional parameters: CF, coronary flow.
*P < .05 compared with the standard cardioplegia group (ANOVA).
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phocreatine. Analysis was performed with Waters Maxima 820 soft-
ware and NEC Power Mate 1.
The oxygenated PSS infusion was stopped to induce ischemia,
and 60 mL of 4°C solution was injected into the aorta at a rate of 1
mL/s to begin the 34°C 2-hour ischemic period. Hearts were ran-
domly assigned to receive either standard cardioplegic solution as
controls or preperfusion with a delta opioid agonist, antagonist, or
both. Type 1 and type 2 delta receptor agonists and antagonists were
investigated individually and in combination before standard cardio-
plegia-induced ischemia to better elucidate the action of the myocel-
lular delta opioid receptor.
In the individual opioid agonist-antagonist studies, 1 of 2 delta
opioid agonists, either the delta-2 D-Ala2-Leu-5-enkephalin
(DADLE) or the delta-1 D-pen2,5-enkephalin (DPDPE), were
administered at 2 mmol/L over 15 minutes (22.7 mg/20 mL PSS).
Other hearts received naltrexone, a nonselective opioid antagonist,
alone (as negative controls) in doses of 2 × 10–4 to 2 × 10–6 mmol/L
over 15 minutes.
In the combined opioid agonist-antagonist studies, naltrexone
was given in vivo 30 minutes before DADLE infusion and coad-
ministered with DADLE infusion for 15 minutes before the 2 hours
of ischemia. The involvement of specific delta opioid receptors
was further delineated by comparing naltrexone, which blocks
both delta 1 and 2; 7-benzylidene-7-dehydronaltrexone hydrochlo-
ride (BNTX), a selective delta 1 blocker; or naltriben-methane sul-
fonate (NTB), a delta 2 blocker, just before DADLE infusions. The
doses of opioids and antagonists were selected by means of stan-
dard opioid dosing and our prior studies.1,2,4,5
The cardioplegic solution contained 109.0 mmol/L NaCl, 25.0
mmol/L KCl, 21.9 mmol/L NaHCO3, 16.0 mmol/L MgCl2, and 0.8
mmol/L CaCl2. On completion of the 2-hour ischemic period, hearts
were reperfused with oxygenated PSS at 37°C. To assess the degree
of functional recovery in each group, hemodynamic data were record-
ed every 15 minutes for 45 minutes and compared with baseline data.
In an attempt to identify delta opioid receptor expression in the
myocardium, immunohistopathologic staining of anti-delta fluo-
rescent-labeled antibodies was used on myocardial and brain tis-
sue from these rabbits. Additionally, because the specific delta 2
receptor has not been specifically fully characterized and no anti-
bodies to it exist, iodine 125 (125I)–radiolabeled DADLE was
infused into animals to identify DADLE/delta 2–receptor distrib-
ution in the animal. Blinded evaluation of electron micrographs
was used to compare ultrastructural changes in control and opi-
oid-pretreated myocytes. Data are expressed as means ± standard
deviation. Statistical analysis for continuous variables was evalu-
ated with analysis of variance (ANOVA; the Scheffé test). All ani-
mals received humane care in compliance with the “Principles of
Laboratory Animal Care” formulated by the National Society for
Medical Research.
Results
There were no differences in any metabolic or functional
indices during preischemia baseline between groups. Table
1 summarizes the postischemic metabolic and functional
recovery results. Compared with standard cardioplegia con-
trol hearts, hearts pretreated with DADLE had markedly
improved isovolumic left ventricular pressure generation
(LVDP: 36 ± 3 vs 65 ± 5 mm Hg, respectively; P < .01).
Conversely, compared with control hearts, those hearts pre-
treated with the opioid antagonist naltrexone revealed a
functional depression of LVDP (36 ± 3 vs 17 ± 5 mm Hg, P
< .05). Fittingly, when DADLE and naltrexone were coad-
ministered, the above individual effects on LVDP were
negated, and the functional recovery was similar to that of
standard cardioplegia (36 ± 3 vs 42 ± 4 mm Hg, P = not sig-
nificant). The end-diastolic pressures at baseline versus that
Figure 1. 125I-labeled DADLE timed distribution at 3 minutes, 15 min-
utes, 30 minutes, 1 hour, and 2 hours after infusion, as well as excre-
tion in the bile (b) and urine (u) at 2 hours. At 3 minutes, there is ini-
tial uptake in the liver (arrow), with subsequent later excretion in the
intestine (small arrows). Note the intense early uptake in the myo-
cardium at 15 minutes (large triangle), which persists for 2 hours.
Figure 2. Electron microscopy of cardiac muscle after 2 hours of
global ischemia and reperfusion. A, DADLE-treated hearts have
unremarkable morphology, with near-normal myofibrillar archi-
tecture. (Original magnification 10,000×.) B, Control hearts, even
at lower power, reveal numerous ultrastructural changes indica-
tive of ischemia-reperfusion injury, as demonstrated by the loss of
myofibrils. The mitochondria are swollen with large amorphous
densities, which is suggestive of irreversible injury.
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at the postischemic recovery period in control, DADLE-
treated, and naltrexone-treated hearts were similar (10 vs
14, 13, and 17 mm Hg, respectively; P = not significant).
Figure 1 suggests the presence of specific myocardial
DADLE/delta 2 receptors. 125I-radiolabeled DADLE
infused intravenously revealed prompt uptake in the heart
that persisted for up to 2 hours. Immunohistopathologic
staining of anti-delta (nonspecific type 1 and 2) fluorescent-
labeled antibodies used on rabbit myocardial and brain tis-
sue revealed scant staining in the heart but good control
delta staining in the brain.
Ultrastructural preservation was significantly improved with
DADLE pretreatment compared with that seen in control hearts
(Figure 2). Blinded assessment denoted better preservation of
subcellular structures with less interstitial edema formation and
more normal myofibrillar structure in the DADLE group.
Opioid untreated control hearts reveal numerous ultrastructural
changes indicative of ischemic injury, as demonstrated by
myofibrillar loss. Furthermore, the mitochondria were swollen
with large amorphous densities, which is suggestive of irre-
versible injury. There were no significant differences in
nucleotide levels or interstitial pH levels between groups
because these were both significantly but equally decreased
from the preischemic period with or without opioid protection.
Furthermore, after Langendorff solution delivery, ischemia, and
reperfusion, heart weight and water content were not different
between opioid-pretreated and control groups.
Discussion
Mammalian hibernation in endotherms is a unique physiolog-
ic state characterized by depressed body temperature, respira-
tion, cardiovascular function, and general metabolism.1-6
Interestingly, hibernators avoid freezing, remain metabolically
regulated, and arouse spontaneously at euthermia with normal
levels of systemic function and metabolic activity. Dawe and
Spurrier7 identified the presence of a hibernation trigger-like
substance circulating in the plasma of hibernating ground
squirrels. When this was administered to nonhibernating ani-
mals, a metabolic state similar to hibernation was induced.8
Further evidence indicates that this molecule initiates its
potent metabolic inhibitory effects through specific membrane
opioid receptors and is a small, thermolabile, protease-sensitive,
nuclease-insensitive protein.9,10 These alterations could be
blocked or restricted by the infusion of opiate antagonists, such
as naloxone and naltrexone.11,12 Hibernation may specifically
involve the delta opioid receptor because mu opioid agonists,
such as morphine and morphiceptin, can actually block hiber-
nation.13,14 These mu agonists will preferentially occupy delta
opioid receptor sites.15 The cellular physiology of mammalian
hibernation very closely parallels that of the altered myocyte
physiology seen with hypothermic global ischemia. Unlike the
poor functional response to prolonged ischemia in cardiac
surgery, the drastic subcellular and molecular changes of
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reduced coronary flow, hypoxia, high-energy phosphate deple-
tion, and volume shifts are well tolerated during hypothermic
mammalian hibernation. This physiologic paradox has been the
impetus to further elucidate the role of opioids in myocyte
metabolism and preservation.
Delta opioid receptors are known to exist in minimal
amounts in many peripheral organs, including the heart.
Our results in the present study confirm previous reports
that general opioid peptides and opioid receptors are found
within the myocardium, where they may exert local physi-
ologic effects.1-6,16-20 A previous report using tritiated
DPDPE has demonstrated the existence of delta opioid recep-
tors in the heart.21 Although only one delta opioid receptor
has been cloned, there are believed to be at least two delta
subtypes. To identify delta opioid receptor subtypes in the
myocardium, we used immunohistopathologic staining of
anti-delta 1 fluorescent-labeled antibodies on myocardial and
brain tissue from rabbits. This study demonstrated abundant
delta 1 opioid receptors in brain tissue but low levels of this
particular stain in the heart. Because the delta 2 receptor has
not presently been characterized and no antibodies to it exist,
we infused 125I-radiolabeled DADLE in an attempt to identi-
fy myocardial delta 2 receptors. This study strongly showed
125I-radiolabeled DADLE uptake in the myocardium (Figure
1). This suggests the presence of opioid receptors of the delta
2 subtype in the heart. Moreover, the present study provides
further lines of evidence suggesting not only that the delta 2
subtype of opioid receptors exists in the heart but also that
their stimulation may mitigate the functional response to
myocardial ischemia. First, the selective delta 1 ligand
DPDPE was relatively inactive, and the anti-ischemic action
of DADLE, which acts at both delta subtypes of opioid recep-
tors, could only be antagonized by the selective delta 2 antag-
onist NTB and not the delta 1 antagonist BNTX.22 Finally,
the existence of separate subtypes of delta opioid receptors
has been further postulated from analgesic testing in animals,
in which the analgesic effect of only delta 2–selective ago-
nists were blocked by antisense oligodeoxynucleotides
directed against cloned delta opioid receptors.23
The current study revealed that the use of the delta opioid
DADLE profoundly improved myocardial functional recovery
after ischemia. When administered alone, naltrexone (an opi-
oid antagonist) did not improve and even decreased postisch-
emic myocardial function. This may relate to an inhibition of
a baseline level of opioid receptor activation. Additionally,
when administered with DADLE, naltrexone blocked its car-
dioprotective effects in a dose-response manner. These results
suggest that naltrexone, with a higher affinity than DADLE, is
acting as a competitive delta receptor antagonist and thus
diminishing the protective effects of exogenously adminis-
tered DADLE.
The involvement of the specific delta opioid receptors in
myocardial preservation was further delineated by comparing
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the universal opioid antagonist naltrexone and the highly
selective delta 1 blocker BNTX or the delta 2 blocker NTB
just before DADLE infusions. Our results, which demonstrat-
ed blocking of myocardial tolerance to ischemia with a spe-
cific delta 2 antagonist but not a delta 1 antagonist, provide
indirect evidence that delta 2 opioid receptors are specifically
involved in myocardial protection.
These results demonstrated improved myocardial toler-
ance to ischemia in a pharmacologic receptor agonist-antago-
nist manner, thereby providing direct evidence that delta opi-
oid receptors are involved in myocardial protection. This
finding builds on the suggestion by our laboratory’s prior
results that opioids confer myocardial protection.1-6 Other
investigators have put forth further corroborating evidence by
using the delta opioid DADLE in multiorgan autoperfusion
systems to extend organ survival time.24,25 Furthermore, suc-
cessful lung transplants from DADLE-treated organ blocs
after 24 hours of ex vivo preservation have been performed.26
Finally, recent reports have provided indirect evidence that
delta opioid receptors are involved in the ischemic precondi-
tioning in the rat and dog myocardium.27,28
Delta opioid receptors belong to the transmembrane gua-
nine nucleotide binding protein (G protein)–linked superfami-
ly of receptors. This binding is known to alter intracellular sig-
nal transduction pathways, which is thought to liberate the
cardioprotective effects of potassium-adenosine
triphosphate–linked potassium channels. However, the precise
mechanism behind the anti-ischemic action of delta opioids
remains elusive. DADLE has been shown to increase the level
of inositol from 1,4,5-triphosphate release of Ca2+ from sar-
coplasmic reticulum in the rat ventricular cardiac myocytes.29
Opioids may also alter contractile protein regulation in
response to the local metabolic environment. Although opioid
receptors are linked to adenylate cyclase activation, it is impor-
tant to note that delta opioids do not exert their action through
an inotropic mechanism. Data from our laboratory revealed
that when DADLE was administered to normal beating nonis-
chemic rabbit hearts in concentrations from 0.01 to 100
mmol/L, there was no inotropic effect and no alteration in pH
or MVO2 levels.
In conclusion, it is tempting to propose that delta opioid
receptors may represent one of nature’s protective mecha-
nisms for tissue survival. Therefore, further elucidation of
their cardioprotective mechanisms in the ischemic and failing
myocardium is warranted.
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